Ormeloxifene versus Medroxyprogesterone Acetate (MPA) in the Treatment of Dysfunctional Uterine Bleeding: A Double-Blind Randomized Controlled Trial
Authors:
- Mb BelladMBMb Bellad
- D MekhalaDMD Mekhala
- Jyotsna ShravageJSJyotsna Shravage
- GanachariGAGanachari
- Ha DhumaleHDHa Dhumale
- 1 April 2011
- journal article
- Published by Jaypee Brothers Medical Publishing in Journal of South Asian Federation of Obstetrics and Gynaecology
- Vol. 3 (1) , 21-24
Abstract
Objective: To find the effectiveness of ormeloxifene vs medroxyprogesterone acetate (MPA) to reduce blood loss in dysfunctional uterine bleeding (DUB).Materials and methods:Design—A double blind randomized controlled trial.Data source—The women attending gynecology OPD in teaching hospital attached to Jawaharlal Nehru Medical College, Belgaum, India for menorrhagia, meeting the selection criteria were enrolled into the study.Randomization—Computer-generated randomization, with block size of two, was done into two groups.Intervention—One group (group A) received capsule ormeloxifene 60 mg to be taken two days a week at an interval of 3 days, and a placebo form of medroxyprogesterone acetate for 21 days starting from day 2 to 5 of the menstrual cycle for three consecutive cycles. Other group (group B) received medroxyprogesterone acetate (MPA) 10 mg for 21 days starting from day 2 to 5 of the menstrual cycle, and a placebo form of ormeloxifene for 2 days a week with an interval of 3 days for three consecutive cycles. The drug and its placebo were in similar capsular form. All the participants were ensured to use the similar type of sanitary napkins, and transvaginal ultrasonography was done to note the endometrial thickness (ET) before and after the drug therapy.Blinding—The department of clinical pharmacy prepared the drug packets and kept the randomization code till the data was analyzed, thus ensuring the double blinding.Outcome: Participants were interviewed during subsequent cycle. Pictorial blood assessment chart (PBAC) score was used to calculate blood loss during menses at the first and subsequent three months.Data analysis: The mean PBAC scores and endometrial thickness were compared in two groups.Results: The mean pretreatment PBAC scores in group A and group B were 262.26 and 238.71 ml respectively. The mean PBAC scores at the end of the study period were 73 and 108 in group A and B respectively, reporting an overall reduction in mean blood loss by 85.7 and 54.76% (p = 0.0205) in group A and B respectively. Thus, there was a significant reduction in blood loss in the group receiving ormeloxifene. The reduction in the mean endometrial thickness was more in ormeloxifene group. However, this was not statistically significant (p = 0.0942).Conclusion: Ormeloxifene is more effective as compared to MPA in reducing the blood loss in the treatment of DUB.Keywords
This publication has 9 references indexed in Scilit:
- Efficacy and safety of ormeloxifene in management of menorrhagia: A pilot studyJournal of Obstetrics and Gynaecology Research, 2009
- Selective Estrogen Receptor Modulators: An Update on Recent Clinical FindingsObstetrical & Gynecological Survey, 2008
- Cyclical progestogens for heavy menstrual bleedingCochrane Database of Systematic Reviews, 2008
- Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding2007
- The Evaluation of Abnormal Uterine BleedingClinical Obstetrics and Gynecology, 2005
- Mechanisms of abnormal uterine bleedingHuman Reproduction Update, 2002
- A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood lossObstetrics & Gynecology, 1995
- Assessment of medical treatments for menorrhagiaBJOG: An International Journal of Obstetrics & Gynaecology, 1994
- Assessment of menstrual blood loss using a pictorial chartBJOG: An International Journal of Obstetrics & Gynaecology, 1990